CPHL logo

Citi Pharma Ltd. CPHL

Market closed

Rs 74.37

-0.18 (-0.24%)

Vol137,709Updated10:3029 Jul 2026

01At a Glance

The headline take on CPHL — valuation, income, returns, and efficiency

Consolidated snapshot

Citi Pharma Ltd. (CPHL) is a Pharmaceuticals company listed on the Pakistan Stock Exchange. As of 29 Jul 2026, CPHL last traded at Rs 74.37 (-0.24% on the day) with a market cap of Rs 16.99B and a free float of 55.0%. Over the last 12 months the stock has returned -8.8%. Cash dividends declared over the trailing 12 months total Rs 3.50/share (yield 4.7%). The stock trades at a P/E of 19.1x. A member of the KSE-100 and KMI-30 indices.

Prices through 29 Jul 2026 · FY data through FY25 · Quarterly through Mar-26

19.1x
Rs 3.90
1Y Return
-8.8%
Rs 16.99B

02Price & Performance

Closing prices across timeframes, returns, and range context

CPHL — Price History

Daily closing series · toggle period below

1M Return-4.5%
3M Return-6.8%
6M Return-16.9%
1Y Return-8.8%
Day's Range84% of range
Rs 74.37
LowRs 73.50
HighRs 74.54
52-Week Range15% of range
Rs 74.37
LowRs 69.25
HighRs 104.25

03Key Metrics

Valuation, profitability, structure, and risk in one grid

19.1xTrailing annual EPS
Rs 3.90Latest annual · basic
Book value n/a
4.71%Rs 3.50/sh trailing 12m
1.11Higher than market
Rs 16.99BMid cap
55.0%126M shares
Ratio n/a
Latest annual
Rs 10Per share

04Dividend History & Yield

Payout track record, yield trend, and upcoming distribution

CPHL has paid Rs 3.50 per share in cash dividends over the trailing 12 months — a 4.7% yield at the last close. Its most recent payout was Rs 3.50/share, announced 02 Oct 2025 with book closure from 21 Oct 2025. Annual dividend-per-share history back to 2016 is charted below.

Latest Payout

Per Share
Rs 3.50
Trailing Yield
4.71%
Payout Ratio
Announced
02 Oct 2025

Dividend Per Share Trend

2021
Rs 1.36
2022
Rs 0.00
2023
Rs 2.50
2024
Rs 3.25
2025
Rs 3.50

Payout History

Source: PSX company payouts

AnnouncedFor PeriodTypeAmountBook Closure
02 Oct 202530 Jun 2025 (YR)CashRs 3.50(35%)21 Oct 2025 – 27 Oct 2025

05Financials & Earnings

Income, balance sheet, and key ratios from published accounts

CPHL's market capitalisation stands at Rs 16.99B as of 29 Jul 2026 down 8.6% over the past 12 months (from Rs 18.59B).

Financial Statements

How OGDC's income and balance sheet have evolved

PKR MillionsFY25FY24FY23FY22FY21FY20Trend
Net Sales / Revenue13,15412,40912,3979,7805,7953,528
Cost of Sales11,13610,82310,8908,4285,0153,091
Gross Profit2,0181,5861,5071,352780437
Administrative Expenses22220418826611194
Operating Profit1,6041,2061,167983571254
EBITDA1,7721,3441,2581,059637306
Other Income19849029219757
Financial Charges330300386714144
Profit Before Tax1,3551,2819571,033500203
Taxation46244829939714859
Profit After Tax892833658636352143
EPS - Basic (Rs)Rs 3.90Rs 3.65Rs 2.88Rs 2.78Rs 1.54Rs 0.63

All figures in PKR millions from published accounts.

Profitability & Returns

Margins, returns on capital, and earnings per share

Latest · FY25

RatioValue
Net profit margin6.8%
Gross profit margin15.3%
EBITDA margin13.5%
EBIT margin12.2%

Net profit margin

Net profit ÷ revenue · %

0.0%1.7%3.4%5.1%6.8%4.1%FY206.1%FY216.5%FY225.3%FY236.7%FY246.8%FY25Period
Earlier periodsLatest period

Financial Health

Coverage, leverage, and the strength of the balance sheet

Latest · FY25

RatioValue
Effective tax rate34.1%

Effective tax rate

Taxation ÷ profit before tax · %

0.0%9.6%19.2%28.8%38.4%29.1%FY2029.6%FY2138.4%FY2231.2%FY2335.0%FY2434.1%FY25Period
Earlier periodsLatest period

Market cap trajectory

Close × current shares outstanding · current Rs 16.99B

Rs 23.25BRs 16.37BRs 9.50BRs 2.62BJul 25Sept 25Nov 25Jan 26Mar 26May 26Rs 16.99B

Valuation & Capital Returns

What the market is paying for CPHL, and what it returns to shareholders

Latest · FY25

RatioValue
Price to earnings21.69x
Price to sales1.47x

Price to earnings

Period-end price ÷ EPS · times

0.00x5.81x11.61x17.42x23.22x23.22xFY218.69xFY228.24xFY2318.66xFY2421.69xFY25Period
Earlier periodsLatest period

06Technical Analysis

Trading signal, moving averages, momentum, and key levels

Trading Signal
SELL

10-day SMA (Rs 74.29) is below the 30-day SMA (Rs 77.79). RSI at 41 sits in the neutral band.

As of29 Jul 2026

PeriodValuevs CurrentPosition
SMA 10Rs 74.29-0.10%Above
SMA 30Rs 77.79+4.60%Below
SMA 60Rs 77.71+4.49%Below
SMA 200Rs 82.08+10.37%Below
41Neutral
0 · Oversold305070100 · Overbought

At 41, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.

MACD
Bearish Cross
  • MACD-1.34
  • Signal-1.17
  • Histogram-0.18
R2Resistance 2
Rs 88.36
18.8%
R1Resistance 1
Rs 81.36
9.4%
NOWCurrent
Rs 74.37
S1Support 1
Rs 69.21
-6.9%
S2Support 2
Rs 64.06
-13.9%

07Leverage Insights

MTS, margin financing, futures open interest, and combined exposure

Rs 137.95M
Margin Trading System
Rs 270.05M
Margin financing
Rs 408.00M
+0.45% MoMMTS + MFS combined

Leverage Composition

MTS · MFS stacked over the selected window

As of 16 Jul 2026

Rs 1.74M
Futures blank sales (Rs)
1.11%
Blank sale ÷ OI
0.76%
Blank sale ÷ free float

Futures Blank Sale Insights

Blank sale value vs OI and free float

08Settlement Insights

UIN-wise settlement concentration and price context

Metrics and charts over the selected trailing window

Latest UIN %59.55%Most recent print
Average · 3M55.73%Mean over window
Change · 3M+19.72%First → last
Range · 3M31.1–85.7%Low–high

Settlement % Trajectory

Solid = UIN settlement % · Dashed = 14-session EMA

As of 16 Jul 2026

Price vs Settlement

Close price (left axis) · UIN settlement % (right axis)

09Share Structure & Capital

Float composition, capital base, and enterprise value

Free float · 55.0%Non-float · 45.0%

Free float vs locked-in holdings

Paid-Up CapitalRs 2.28B
Total Shares228M
126M
55.0%
Year EndJun
Enterprise Value

10About the Company

Business description, governance, and corporate information

Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products.

KSE-100KMI-30Shariah CompliantPharmaceuticals

Corporate Information

  • RegistrarF.D Registrar Services (Pvt.) Ltd.
  • AuditorAslam Malik & Co. Chartered Accountants
  • Websitewww.citipharma.com.pk
  • Address3-KM, Head Balloki Road, Bhai Pheru, Distt Kasur
  • SectorPharmaceuticals
  • Financial Year EndJune

Key People

NameRole
RARizwan Ahmad
CEO
NANadeem Amjad
Chairperson
MRMuhammad Rasheed Alam
Company Secretary

11Recent Announcements

Latest company filings as reported on PSX

Filings and disclosures from the PSX announcement feed

12Peers in Pharmaceuticals

How the cohort is moving — same-sector stocks by market cap

CPHL vs Pharmaceuticals sector median

Median across 14 sector constituents · nulls excluded per metric

MetricCPHLSector median
19.1x16.0x
4.7%4.0%
22.3%
1-Year Return-8.8%-8.7%
Rs 16.99BRs 27.79B

13Frequently Asked Questions

The most common questions investors ask about CPHL

Frequently Asked Questions

CPHL closed at Rs 74.37 on 29 Jul 2026, down 0.24% on the day, within a 52-week range of Rs 69.25–104.25. Prices on this page refresh through the trading day; log in to BSL for live quotes.

Ready to invest in CPHL?

Open a BSL trading account in under 10 minutes

Buy and sell CPHL and 550+ other PSX-listed stocks with low commissions, real-time data, and a concierge research desk backing every trade.

Open Account